

# **Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020**

<https://marketpublishers.com/r/GA1C8014611EN.html>

Date: June 2020

Pages: 2766

Price: US\$ 2,500.00 (Single User License)

ID: GA1C8014611EN

## **Abstracts**

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020

### **SUMMARY**

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides an overview of the Glioblastoma Multiforme (Oncology) pipeline landscape.

Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy and chemotherapy.

### **REPORT HIGHLIGHTS**

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glioblastoma Multiforme - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glioblastoma Multiforme (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 130, 94, 2, 13, 198, 43 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 1, 14, 14, 3, 53 and 9 molecules, respectively. Glioblastoma Multiforme (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (Oncology).

The pipeline guide reviews pipeline therapeutics for Glioblastoma Multiforme (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glioblastoma Multiforme (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glioblastoma Multiforme (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Glioblastoma Multiforme (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Glioblastoma Multiforme (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Glioblastoma Multiforme (GBM) - Overview

Glioblastoma Multiforme (GBM) - Therapeutics Development

Glioblastoma Multiforme (GBM) - Therapeutics Assessment

Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development

Glioblastoma Multiforme (GBM) - Drug Profiles

Glioblastoma Multiforme (GBM) - Dormant Projects

Glioblastoma Multiforme (GBM) - Discontinued Products

Glioblastoma Multiforme (GBM) - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by 1st Bio Therapeutics Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by 1ST Biotherapeutics Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by 4D Pharma Plc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Aadi Bioscience Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by ABM Therapeutics Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Accendatech Au Pty Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Actuate Therapeutics Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by AdastrA Pharmaceuticals Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Adlai Nortye Biopharma Co Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications SA, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories LLC, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Aettis Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Affimed GmbH, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Agenus Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by AiVita Biomedical Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Allianz Pharmascience Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Alterity Therapeutics Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Amal Therapeutics SA, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by MiReven Pty Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Molecular Targeting Technologies Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Molecular Templates Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Moleculin Biotech LLC, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Multimmune GmbH, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Mustang Bio Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Mycenax Biotech Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Nanjing KAEDI Biotech Inc, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Nanjing Legend Biotech Co Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by Nanomerics Ltd, H1 2020

Glioblastoma Multiforme (GBM) - Pipeline by NanoPharmaceuticals LLC, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

1st Bio Therapeutics Inc  
1ST Biotherapeutics Inc  
4D Pharma Plc  
A. Menarini Industrie Farmaceutiche Riunite Srl  
Aadi Bioscience Inc  
AbbVie Inc  
ABM Therapeutics Inc  
Accendatech Au Pty Ltd  
Actuate Therapeutics Inc  
Adastra Pharmaceuticals Inc  
Adlai Nortye Biopharma Co Ltd  
Aduro BioTech Inc  
Advanced Accelerator Applications SA  
Advenchen Laboratories LLC  
Aettis Inc  
Affimed GmbH  
Agenus Inc  
AiVita Biomedical Inc  
Allianz Pharmascience Ltd  
Alterity Therapeutics Ltd  
Amal Therapeutics SA

Amasa Technologies Inc  
Ambrx Inc  
Amgen Inc  
Anew Oncology Inc  
AngioChem Inc  
apceth Biopharma GmbH  
Apexigen Inc  
APIM Therapeutics AS  
Apogenix AG  
Apollomics Inc  
Apotex Inc  
Aptamer Sciences Inc  
Argonaut Therapeutics Ltd  
Arog Pharmaceuticals Inc  
Arrien Pharmaceuticals LLC  
Arrogene Inc  
Astellas Pharma Inc  
AstraZeneca Plc  
Athenex Inc  
Aurora BioPharma Inc  
Avalia Immunotherapies Ltd  
Aveta Biomics Inc  
Avid Chemotherapeutics LLC  
Avidin Ltd  
Basilea Pharmaceutica Ltd  
Batu Biologics Inc  
Bayer AG  
BeiGene Ltd  
Beijing Eastern Biotech Co Ltd  
Berg LLC  
BerGenBio ASA  
Beta Pharma Inc  
Bexion Pharmaceuticals LLC  
BeyondBio Inc  
BeyondSpring Inc  
Bio-Path Holdings Inc  
Bio-Thera Solutions Ltd  
Bioasis Technologies Inc  
Biocon Ltd



BioEclipse Therapeutics Inc  
BioIntegrator Ltd  
BioNTech SE  
Biosion Inc  
Biovista Inc  
BioXpress Therapeutics SA  
Black Diamond Therapeutics Inc  
Boehringer Ingelheim International GmbH  
Boryung ViGenCell Inc  
Boston Biomedical Inc  
BoYuan RunSheng Pharma Hangzhou Co Ltd  
Breakpoint Therapeutics GmbH  
Bristol-Myers Squibb Co  
Candel Therapeutics  
Cantex Pharmaceuticals Inc  
CARsgen Therapeutics Ltd  
CDG Therapeutics Inc  
Cell Medicine Cooperation  
CellCure  
Celldex Therapeutics Inc  
Cellestia Biotech AG  
Cellivity Therapeutics Inc  
Cellmid Ltd  
Cellworks Group Inc  
Celsion Corp  
Celularity Inc  
CHA Biotech Co Ltd  
Cloaked Therapeutics LLC  
CNS Pharmaceuticals Inc  
Cotinga Pharmaceuticals Inc  
Curtana Pharmaceuticals Inc  
Cynata Therapeutics Ltd  
Cytodyn Inc  
CytoVac AS  
Daiichi Sankyo Co Ltd  
Dalriada Therapeutics Inc  
Deciphera Pharmaceuticals Inc  
DEKK-TEC Inc  
DeIMar Pharmaceuticals Inc

Denovo Biopharma LLC  
DevaCell Inc  
Diakonos Research Ltd  
Diffusion Pharmaceuticals Inc  
Diverse Biotech Inc  
Divide and Conquer Ltd  
DNAtrix Inc  
Dong-A ST Co Ltd  
Dr. Reddy's Laboratories Ltd  
DualTpharma BV  
Ecrins Therapeutics SAS  
EirGenix Inc  
Eisai Co Ltd  
Eli Lilly and Co  
Empirica Therapeutics Inc  
ENB Therapeutics LLC  
EnduRx Pharmaceuticals Inc  
EnGeneIC Ltd  
Enochian Biosciences Inc  
Enterome Bioscience SA  
EntreChem SL  
EpicentRx Inc  
EpiDrugs Discovery  
Epigene Therapeutics Inc  
Epygen Biotech Pvt Ltd  
ERC Belgium SA  
ERYTECH Pharma SA  
Eutilex Co Ltd  
Ever Supreme Bio Technology Co Ltd  
Everfront Biotech Inc  
Evgen Pharma Plc  
F. Hoffmann-La Roche Ltd  
Falcon Therapeutics Inc  
Faron Pharmaceuticals Oy  
Felicitex Therapeutics Inc  
FirstString Research Inc  
Flag Therapeutics Inc  
Flavocure Biotech LLC  
Fujifilm Holdings Corp

Fusion Antibodies Plc  
Galapagos NV  
GC Pharma  
Gene Techno Science Co Ltd  
Geneius Biotechnology Inc  
Genenta Science srl  
Genentech Inc  
Geneos Therapeutics Inc  
Genexine Inc  
Genisphere LLC  
Genomefrontier Therapeutics Inc  
Genoscience Pharma  
Gilead Sciences Inc  
GlaxoSmithKline Plc  
Gliocure SAS  
Gliopharma ApS  
GO Therapeutics Inc  
GtreeBNT Co Ltd  
Guangdong Zhongsheng Pharmaceutical Co Ltd  
Hamlet Pharma AB  
Hanmi Pharmaceuticals Co Ltd  
Hebei Senlang Biotechnology Inc Ltd  
Hemispherian AS  
Hope Biosciences LLC  
HOX Therapeutics Ltd  
Humanigen Inc  
Hunan Siweikang Therapeutics Ltd  
Hutchison MediPharma Ltd  
Hyperstem Therapeutics Inc  
i2 Pharmaceuticals Inc  
Ibex Biosciences LLC  
Immatix Biotechnologies GmbH  
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd  
Immunitor Inc  
ImmunityBio Inc  
ImmunoCellular Therapeutics Ltd  
Immunomedics Inc  
Immunomet Therapeutics Inc  
Immunomic Therapeutics Inc

ImmunoRestoration LLC  
IMV Inc  
Imvax Inc  
Incysus Therapeutics Inc  
Incyte Corp  
Infinity Pharmaceuticals Inc  
Innovation Pharmaceuticals Inc  
Inovio Pharmaceuticals Inc  
InSight Biopharmaceuticals Ltd  
Instituto Biomar SA  
IntelliStem Technologies Inc  
Intensity Therapeutics Inc  
InterLeukin Combinatorial Therapies Inc  
Invectys SA  
Ipsen SA  
ISA Pharmaceuticals BV  
Istari Oncology Inc  
ITM Isotopen Technologien Munchen AG  
Janpix Inc  
Jay Pharma Inc  
Jiangsu Aosaikang Pharmaceutical Co Ltd  
Jiangsu Kanion Pharmaceutical Co Ltd  
Johnson & Johnson  
Joseah Biopharma Co Ltd  
Jubilant Therapeutics Inc  
Juno Therapeutics Inc  
JW CreaGene Co Ltd  
Kadmon Corp LLC  
Kalgene Pharmaceuticals Inc  
Kancera AB  
Karus Therapeutics Ltd  
Karyopharm Therapeutics Inc  
Kazia Therapeutics Ltd  
Komipharm International Co Ltd  
Kringle Pharma Inc  
Kyorin Pharmaceutical Co Ltd  
Lacerta Therapeutics Inc  
Lantern Pharma Inc  
Lauren Sciences LLC

LeadInvent Pharma Inc  
Lin Bioscience Inc  
Lipopharma Therapeutics SL  
Lixte Biotechnology Holdings Inc  
Lumos Pharma Inc  
Luye Pharma Group Ltd  
LynkCell Inc  
MacroGenics Inc  
Marino Biotechnology Co Ltd  
Medesis Pharma SA  
Medical Guidance Systems LLC  
Medicenna Therapeutics Corp  
Medicon Pharmaceuticals Inc  
Medisun Precision Medicine Ltd  
MedPacto Inc  
MELEMA Pharma GmbH  
Merck & Co Inc  
Merck KGaA  
Meryx Inc  
Metis Precision Medicine  
MetVital Inc  
MGC Pharmaceuticals Ltd  
Midatech Pharma Plc  
Millennium Pharmaceuticals Inc  
MimiVax LLC  
MiReven Pty Ltd  
Molecular Targeting Technologies Inc  
Molecular Templates Inc  
Moleculin Biotech LLC  
Multimmune GmbH  
Mustang Bio Inc  
Mycenax Biotech Inc  
Nanjing Bioheng Biotech Co Ltd  
Nanjing KAEDI Biotech Inc  
Nanjing Legend Biotech Co Ltd  
Nanomerics Ltd  
NanoPharmaceuticals LLC  
NantKwest Inc  
Nascent Biotech Inc

NatureWise Biotech & Medicals Corp  
Nektar Therapeutics  
Neonc Technologies Inc  
NMS Group SpA  
Northlake International LLC  
Northwest Biotherapeutics Inc  
Novartis AG  
Novellus Inc  
Noxopharm Ltd  
Noxxon Pharma AG  
NuvOx Pharma LLC  
OGD2 Pharma SAS  
Omniox Inc  
OncoArendi Therapeutics SA  
Oncoceutics Inc  
Oncodesign SA  
Oncologie Inc  
Oncology Venture U.S. Inc  
Oncolytics Biotech Inc  
Onconova Therapeutics Inc  
OncoResponse Inc  
Oncorus Inc  
OncoRx Pharmaceuticals Inc  
OncoSynergy Inc  
Oncotelic Inc  
Oncternal Therapeutics  
Ono Pharmaceutical Co Ltd  
Origenis GmbH  
Oryx GmbH & Co KG  
Ossianix Inc  
Ovensa Inc  
Parabon NanoLabs  
Pascal Biosciences Inc  
Patrys Ltd  
PENAO Pty Ltd  
Peptomyc SL  
Pfizer Inc  
Phanes Therapeutics Inc  
Pharma Mar SA

PharmAbcine Inc  
Pharmicell Co Ltd  
Phoenix Biotechnology Inc  
Phost'IN SAS  
Photonamic GmbH & Co KG  
Plex Pharmaceuticals Inc  
Plus Therapeutics Inc  
Prelude Therapeutics Inc  
Prestige BioPharma Pte Ltd  
Preveceutical Medical Inc  
Primevax Immuno Oncology Inc  
PTC Therapeutics Inc  
Puma Biotechnology Inc  
QED Therapeutics Inc  
Quadriga BioSciences Inc  
Refuge Biotechnologies Inc  
Regeneron Pharmaceuticals Inc  
Reglagene LLC  
Regulus Therapeutics Inc  
ReNeuron Group Plc  
Revolution Medicines Inc  
Rgenix Inc  
Richter Gedeon Nyrt  
Ridgeline Therapeutics LLC  
Rottapharm Biotech Srl  
Rznomics Inc  
Safe Save Medical Cell Sciences & Technology Co Ltd  
Salarius Pharmaceuticals Inc  
Sanofi  
Sapience Therapeutics Inc  
Scancell Holdings Plc  
Seagull Labs (I) Pvt Ltd  
Seneca Therapeutics Inc  
Sentinel Oncology Ltd  
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd  
Shenzhen BinDeBio Ltd  
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd  
SignalChem Lifesciences Corp  
SignPath Pharma Inc

Silenseed Ltd  
Singh Biotechnology LLC  
SixFold Bioscience Ltd  
SL Bigen Inc  
SL VaxiGen Inc  
SOM Biotech SL  
Speer Medical Technologies LLC  
STAT3 Therapeutics Inc  
Stcube Inc  
Stella Therapeutics Inc  
StemGen SpA  
Sumitomo Dainippon Pharma Co Ltd  
Suntec Medical (Taiwan) Inc  
Susavion Biosciences Inc  
Suzhou JiSheng Pharmaceutical Co Ltd  
Suzhou Neupharma Co Ltd  
Suzhou Stainwei Biotech Inc  
Synactix Pharmaceuticals Inc  
Synchronicity Pharma Inc  
Synermore Biologics Co Ltd  
SyntheX Inc  
Tactical Therapeutics Inc  
Taiho Oncology Inc  
Targinta AB  
Telo Therapeutics Inc  
Telomium SAS  
The Palo Alto Research Center  
TheraBiologics Inc  
Theralase Technologies Inc  
Therapeia GmbH & Co KG  
TheraPten Biosciences Inc  
Titan Pharmaceuticals Inc  
Tmunity Therapeutics Inc  
TRACON Pharmaceuticals Inc  
Transcode Therapeutics Inc  
Transgene SA  
Transtarget Inc  
Turning Point Therapeutics Inc  
TVAX Biomedical Inc



Tyme Technologies Inc  
Upsher-Smith Laboratories Inc  
Vanquish Oncology Inc  
Vascular Biogenics Ltd  
Vault Pharma Inc  
Vaximm AG  
VBI Vaccines Inc  
Vigeo Therapeutics Inc  
VirusCure Therapeutics Ltd  
Vivacitas Oncology Inc  
Wayshine Biopharma Inc  
WindMIL Therapeutics Inc  
WPD Pharmaceuticals Inc  
X4 Pharmaceuticals Inc  
Xonovo Inc  
Yooyoung Pharm Co Ltd  
Zata Pharmaceuticals Inc  
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd  
ZIOPHARM Oncology Inc

## I would like to order

Product name: Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/GA1C8014611EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA1C8014611EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970